Clinical trials: Pediatric Asthma
Asthma
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma.
- Trial name
- NCT00392288
- Testing
- Ciclesonide
- Where
- 6 sites in United States, Hungary and 4 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma
Asthma
Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population
The objective of this study is to compare asthma-related exacerbations (emergency department (ED) or inpatient (IP) visit) and related cost in pediatric patients aged 4-11 years that received either fluticasone propionate 44 mcg…
- Trial name
- NCT01328964
- Testing
- Fluticasone propionate, Budesonide, Montelukast
- Volunteers
- 9,906 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in…
- Trial name
- NCT00448435
- Testing
- GW815SF HFA MDI, salmeterol and fluticasone propionate
- Where
- 8 sites in Japan
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Asthma
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
The study is to evaluate the chronic-dose efficacy and the safety of Albuterol MDPI compared to placebo in pediatric participants with asthma.
- Trial name
- NCT02126839
- Testing
- Albuterol MDPI, ProAir HFA inhaler
- Where
- 52 sites in United States, Thailand
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
- Trial name
- NCT00583947
- Testing
- arformoterol, levalbuterol
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm.
- Trial name
- NCT02150499
- Testing
- levalbuterol tartrate HFA inhalation aerosol
- Where
- 17 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Safety and Blood Level Study of Unit Dose Budesonide
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.
- Trial name
- UDB P101 (NCT00627679)
- Testing
- Budesonide Inhalation Suspension, MAP0010 low dose, MAP0010 intermediate dose
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Allergan
Asthma
Pediatric Ease of Use ELLIPTA Items
A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic subjects.
- Trial name
- NCT03315572
- Testing
- Interviewer administered version of ease of use items, Self-administered version of ease of use items, Caregiver version of ease of use items
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Wheezing, Reactive Airway Disease
A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
The primary objective of this study is to evaluate budesonide levels in the blood following inhalation of single doses of VR647 Inhalation Suspension in children with wheezing, reactive airway disease or mild asthma using a…
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Trial name
- NCT03421730
- Testing
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Vectura Limited
Asthma
Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)
a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids
- Trial name
- NCT00832455
- Testing
- montelukast sodium
- Volunteers
- 445 people
- Sponsor
- Organon and Co
Asthma
Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years…
- Trial name
- NCT01453023
- Testing
- Fluticasone Furoate, Fluticasone Furoate/Vilanterol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Asthma
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma is a chronic inflammatory disease of airways and lungs that results in hyper-reactivity and clinically relevant episodes of wheezing.
- Trial name
- NCT03478657
- Testing
- ELLIPTA DPI, Ease of use questionnaires
- Where
- 19 sites in United States, Canada
- Volunteers
- 222 people
- Sponsor
- GlaxoSmithKline
Asthma
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone…
- Trial name
- VESTRI (NCT01462344)
- Testing
- ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg
- Where
- 530 sites in United States, Argentina and 30 more
- Volunteers
- 6,250 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled, single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with persistent asthma.
- Trial name
- NCT01899144
- Testing
- Albuterol Spiromax, ProAir HFA
- Where
- 22 sites in United States
- Volunteers
- 61 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use
The primary objective of this study is to determine ex vivo the amount of fluticasone deposited onto a filter (delivered dose) interposed between the OptiChamber Diamond Valved Holding Chamber (VHC) mouthpiece and the subject's…
- Trial name
- NCT01714063
- Testing
- Pressurized Metered-Dose Inhaler
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Philips Respironics
Asthma, Asthma in Children
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
- Trial name
- NCT04450108
- Testing
- Vivatmo pro FeNO Test
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bosch Healthcare Solutions GmbH
Asthma
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
This is a multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with oral prednisone…
- Trial name
- NCT01687296
- Testing
- fluticasone propionate inhalation solution, oral prednisone, salbutamol
- Where
- 11 sites in China
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
This study consists of a 3-year double-blind phase during which patients will receive atopic dermatitis (AD) treatment either with pimecrolimus cream 1% long-term management (LTM) or with a conventional corticosteroid-based…
- Trial name
- NCT00124709
- Testing
- Pimecrolimus, Corticosteroid
- Where
- 36 sites in United States
- Volunteers
- 1,091 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
House Dust Mite Allergy Trial In Children
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
- Conditions
- Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MATIC (NCT04145219)
- Testing
- Sublingual allergy immunotherapy tablet
- Where
- 113 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,460 people
- Sponsor
- ALK-Abelló A/S